Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 10/20 | 0.51 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | BCL6 | P41182 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.39 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24140809 | 1.00 | MTOR (0.51) | MTORERN1PIK3CABCL6MAPT | |
| SCHEMBL25313454 | 0.82 | PRMT5 (0.52) | MTORERN1AMY1ASMPD3 | |
| SCHEMBL30472120 | 0.82 | PRMT5 (0.52) | MTORERN1AMY1ASMPD3 | |
| SCHEMBL30472077 | 0.82 | ERN1 (0.48) | MTORERN1MAPTKDM4ECYP3A4 | |
| SCHEMBL24140520 | 0.82 | ERN1 (0.48) | MTORERN1MAPTKDM4ECYP3A4 | |
| SCHEMBL24141207 | 0.78 | MTOR (0.48) | MTORERN1FYNSMPD3 | |
| SCHEMBL24141205 | 0.78 | CLK2 (0.47) | MTORERN1AMY1ASMPD3 | |
| SCHEMBL24141173 | 0.77 | ALDH1A1 (0.54) | MAPTFYNKDM4ECYP3A4HPGD | |
| SCHEMBL24141208 | 0.76 | FYN (0.46) | MTORERN1PIK3CAMAPTFYN | |
| SCHEMBL1310166 | 0.68 | MTOR (1.00) | MTORERN1PIK3CAMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | FEN1, ERCC4, DCLRE1B | MTOR 3934/4885ERN1 258/4885PIK3CA 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.